Delivery Order SPE2DB20D3103-SPE2DB25FM9T1
Award Date
3/7/25
Potential Completion Date
3/28/25
Potential Value
$11K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of HYPERRAB 300 UNIT/ML VIALML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $5,582.85 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, Corporate Office Division, a major pharmaceutical distributor, on June 13, 2024. The contract has an ultimate completion date of July 8, 2024 and was not set aside for any special designation. Amerisourcebergen holds a larger $999,999,999.00 Indefinite Delivery...
This federal contract award is a $1,039.53 Firm Fixed Price Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of HYPERRAB 300 UNIT/ML VIALML, a medical product, with a completion date of February 25, 2025. The contract is not designated with a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,659.62 firm fixed-price delivery order is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a pharmaceutical product. The contract has a completion date of January 3, 2025 and was awarded on December 11, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $38,865.20 firm fixed-price delivery order is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a critical medical product. The contract has an ultimate completion date of December 26, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award is for the delivery of HYPERRAB 300 UNIT/ML VIAL 5ML pharmaceutical products to the Defense Logistics Agency (DLA) Troop Support Medical facilities. The $11,270.10 firm fixed price delivery order was awarded to AmerisourceBergen Drug Corp, a for-profit organization and a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation. The award is part of an Indefinite Delivery Contract (IDC) held by AmerisourceBergen Drug Corp, valued at up...
This federal contract award to Amerisourcebergen Drug Corp is a Delivery Order under an Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical. The award, valued at $1,790.80, is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a specialized pharmaceutical product. The contract has an ultimate completion date of March 28, 2025 and is a Firm Fixed Price arrangement. This award is part of Amerisourcebergen's larger $999,999,999 IDC with the DLA, which...
The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a firm fixed-price delivery order contract worth $8,932.56 to supply HYPERRAB 300 UNIT/ML VIALML, a pharmaceutical product. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $999,999,999.00, which serves as the primary vehicle for Amerisourcebergen to provide pharmaceuticals and medical supplies to DLA Troop Support Medical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical distribution company Amerisourcebergen Corporation. The $9,391.75 Delivery Order is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a pharmaceutical product. The contract is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. This...
This federal contract award is for the delivery of HYPERRAB 300 UNIT/ML VIAL 5ML, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The $3,601.80 firm-fixed-price contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on October 12, 2021, with a completion date of November 2, 2021. The contract has no set-aside designation, indicating it was awarded through full and open competition. AmerisourceBergen Drug Corp is a subsidiary of the...
This federal contract award is for the delivery of HYPERRAB 300UNIT/ML 1S medical supplies to the Defense Logistics Agency (DLA) Troop Support Medical. The contract, with a ceiling value of $14,326.48, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA, valued at $999,999,999 and running through November...